Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy? [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
in billions of dollars in revenue and profit annually from its CF drugs. And that's likely to continue thanks to solid technology and a late-stage candidate that might even beat Vertex's current products in efficacy. But Vertex is no longer just about one treatment area. The company last year won approval for a blood-disorder treatment, Casgevy, along with partner CRISPR Therapeutics . And just recently, it made two big moves that could advance its position in other high-potential areas. Considering this, is the stock a buy right now? Let's look at each of these Vertex moves and find out. 1. Advancing a potential blockbuster to treat pain Vertex's next big opportunity involves treating one of the most common problems: pain. The company decided to address this market because of the current lack of treatments beyond over-the-counter medicines, which sometimes lack efficacy, and opioid painkillers, which are linked to addiction. So there's clearly room for an alternative. The b
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade) [Seeking Alpha]Seeking Alpha
- Vertex (VRTX) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note [Yahoo! Finance]Yahoo! Finance
- Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth [Reuters]Reuters
- Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 2/21/24 - Beat
CRSP
Sec Filings
- 4/17/24 - Form 4
- 4/15/24 - Form 144
- 4/10/24 - Form SC
- CRSP's page on the SEC website